Myriad to Announce Fiscal Third-Quarter 2019 Financial Results on May 7, 2019
April 23 2019 - 4:05PM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized
medicine, today announced that it will hold its fiscal
third-quarter 2019 sales and earnings conference call with
investors and analysts at 4:30 p.m. EDT on Tuesday, May 7,
2019. During the call, Mark C. Capone, president and CEO, and
Bryan Riggsbee, CFO, will provide an overview of Myriad’s financial
performance for the fiscal third-quarter and provide a business
update.
To listen to the earnings call, interested parties in the United
States may dial 800-908-1487 or +1 303-223-0120 for international
callers. All callers will be asked to reference reservation
number 21920022. The conference call also will be available through
a live webcast and a slide presentation pertaining to the earnings
call also will be available under the investor section of our
website at www.myriad.com. A replay of the call will be
available two hours after the end of the call for seven days and
may be accessed by dialing 800-633-8284 within the United States or
+1 402-977-9140 for international callers and entering reservation
number 21920022.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
five strategic imperatives: building upon a solid hereditary
cancer foundation, growing new product volume, expanding
reimbursement coverage for new products, increasing RNA kit revenue
internationally and improving profitability with Elevate
2020. For more information on how Myriad is making a
difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris,
Foresight and Prequel are trademarks or registered trademarks of
Myriad Genetics, Inc. or its wholly owned subsidiaries in the
United States and foreign countries. MYGN-F, MYGN-G.
Media Contact: |
Ron Rogers(801) 584-3065 rrogers@myriad.com |
Investor Contact: |
Scott Gleason(801) 584-1143sgleason@myriad.com |
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024